ZEB1
ZEB1 (Zinc finger E-box-binding homeobox 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Nasopharyngeal carcinoma, Multiple myeloma and 4 more.
Overview
Acts as a transcriptional repressor. Inhibits interleukin-2 (IL-2) gene expression. Enhances or represses the promoter activity of the ATP1A1 gene depending on the quantity of cDNA and on the cell type.
CIViC holds 9 clinical evidence items and 0 assertions across 3 variants, naming Doxorubicin, Salinomycin, Gemcitabine and Cytarabine and others. IntOGen calls it a driver in 6 cohorts (5 activating, 1 loss-of-function), covering Glioblastoma Multiforme, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Plasma Cell Myeloma, Small Cell Lung Cancer.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ZEB1 (Zinc finger E-box-binding homeobox 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Nasopharyngeal carcinoma, Multiple myeloma and 4 more.
- 1 · What it is
ZEB1 (Zinc finger E-box-binding homeobox 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer, Nasopharyngeal carcinoma, Multiple myeloma and 4 more.
- 2 · What goes wrong in cancer
Acts as a transcriptional repressor. Inhibits interleukin-2 (IL-2) gene expression.
- 3 · How drugs use it
No product in this corpus aims at ZEB1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:11642 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P37275 (protein name, function text, keywords and locations (REST API)); CIViC gene ZEB1 (9 evidence items, 0 assertions, 3 variants; diseases: Mantle Cell Lymphoma, Colon Cancer, Cancer (GraphQL API, CC0)); IntOGen ZEB1 (driver in 6 cohorts (Act 5, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Acts as a transcriptional repressor. Inhibits interleukin-2 (IL-2) gene expression. Enhances or represses the promoter activity of the ATP1A1 gene depending on the quantity of cDNA and on the cell type. Represses E-cadherin promoter and induces an epithelial-mesenchymal transition (EMT) by recruiting SMARCA4/BRG1. Represses BCL6 transcription in the presence of the corepressor CTBP1. Positively regulates neuronal differentiation. Location: Nucleus (UniProt). Locus 10p11.22 (HGNC).
- Colorectal cancer: CIViC evidence names this disease
- Nasopharyngeal carcinoma: IntOGen driver in 1 cohort (NPC)
- Multiple myeloma: IntOGen driver in 1 cohort (PCM)
- Mantle cell lymphoma: CIViC evidence names this disease
- Non-small-cell lung cancer: IntOGen driver in 2 cohorts (LUAD, LUSC)
- Glioma & glioblastoma: IntOGen driver in 1 cohort (GBM)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 7 therapies; IntOGen calls it an activating (Act) driver in 5 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 9 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ZEB1" OR ABSTRACT:"ZEB1" OR TITLE:"zinc finger E-box binding homeobox 1" OR ABSTRACT:"zinc finger E-box binding homeobox 1" OR TITLE:"Zinc finger E-box-binding homeobox 1" OR ABSTRACT:"Zinc finger E-box-binding homeobox 1" OR TITLE:"AREB6" OR ABSTRACT:"AREB6" OR TITLE:"NIL-2-A" OR ABSTRACT:"NIL-2-A" OR TITLE:"Zfhep" OR ABSTRACT:"Zfhep") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ZEB1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetSP140
Shares Mantle cell lymphoma, CIViC, IntOGen, Multiple myeloma.
- TargetPSMD4
Shares Mantle cell lymphoma, CIViC, Multiple myeloma, Colorectal cancer.
- TargetHGF
Shares Invasion: proteases, adhesion & the invasive front, Glioma & glioblastoma, CIViC, IntOGen.
- TargetCYLD
Shares Nasopharyngeal carcinoma, IntOGen, Multiple myeloma, Colorectal cancer.
- TargetBIRC3
Shares Mantle cell lymphoma, CIViC, IntOGen, Non-small-cell lung cancer.
- TargetTET1
Shares Nasopharyngeal carcinoma, CIViC, IntOGen, Colorectal cancer.
- TargetUBR5
Shares Mantle cell lymphoma, CIViC, IntOGen, Colorectal cancer.
- TargetMEF2B
Shares Mantle cell lymphoma, CIViC, IntOGen.